For A Lung Cancer, Drug Treatment May Be Within Reach

Lung Cancer

A comprehensive study of the genetics of a common lung cancer finds that more than half the tumors have mutations that might be treated by drugs that are already in the pipeline or that could be developed.

Sections:  living   
Topics:  cancer   drugs   genetics   health   lung cancer   medical   tumor   
RELATED ARTICLES
  • Most people aren't meeting exercise guidelines
    Most adults in the USA aren't meeting the federal physical activity recommendations for both aerobic exercise and muscle-strengthening activity, according to government statistics out today. About 79% of adults don't meet the physical activity guidelines that advise getting at least 2½ hours a week of moderate-intensity aerobic activity such as brisk walking, or one hour and 15 minutes a week of vigorous-intensity aerobic activity, such as jogging. More
  • US suicide rate rose sharply among middle-aged
    Health officials say suicides among middle-aged Americans climbed at a startling rate over the past decade, a period that included the recession. Overall, the suicide rate for the age group jumped 28 percent from 1999 to 2010. And among whites, it shot up 40 percent.... More
  • Cost of feeding a family of four: $146 to $289 a week
    Latest statistics give a range of prices for feeding a family of four a healthy diet. The cost of feeding a family of four a healthy diet can run $146 to $289 a week, according to the latest numbers from the U.S. More
  • 2-year-old girl gets windpipe made from stem cells
    A 2-year-old girl born without a windpipe now has a new one grown from her own stem cells, the youngest patient in the world to benefit from the experimental treatment.... More
  • Study: New bird flu jumped directly from chickens
    Chinese scientists have for the first time found strong evidence of how humans got infected with a new strain of bird flu: from chickens at a live market. In a small study of four patients who caught the new H7N9 virus, Chinese scientists compared swabs from birds at live markets in eastern China to virus samples from patients. More
BING NEWS:
  • EU regulators approve BeiGene's tislelizumab for lung cancer
    EU regulators have approved BeiGene's (BGNE) tislelizumab for the treatment of certain types of non-small cell lung cancer. Read more here.
    04/23/2024 - 5:15 am | View Link
  • Alecensa approved as first and only anaplastic lymphoma kinase inhibitor for non-small cell lung cancer
    The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small ...
    04/23/2024 - 2:40 am | View Link
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung ...
    04/23/2024 - 1:07 am | View Link
  • Alecensa Approved as Adjuvant Treatment for ALK+ NSCLC
    The FDA has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small cell lung cancer.
    04/22/2024 - 3:15 am | View Link
  • First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution
    With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting.
    04/20/2024 - 5:06 pm | View Link
  • More
BING SEARCH:
  • Alecensa Approved as First and Only ALK inhibitor for NSCLC
    Apr 22, 2024, 10:48 pm. MONDAY, April 22, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The approval was based on positive results from the phase 3 ...
    04/22/2024 - 6:47 pm | View Website
  • Non-Small Cell Lung Cancer Treatment
    Non-small cell lung cancer (NSCLC) treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Laser therapy, photodynamic therapy, cryosurgery, and electrocautery may be used. Learn more about NSCLC in this expert-reviewed summary.
    04/22/2024 - 11:44 am | View Website
  • Lung cancer
    Treatment. Treatment for lung cancer usually begins with surgery to remove the cancer. If the cancer is very large or has spread to other parts of the body, surgery may not be possible. Treatment might start with medicine and radiation instead. Your healthcare team considers many factors when creating a treatment plan.
    04/22/2024 - 9:14 am | View Website
  • Sotorasib is First KRAS Inhibitor Approved by FDA
    The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is most common in lung cancer.
    04/22/2024 - 3:16 am | View Website
  • Targeted Drug Therapy for Non-Small Cell Lung Cancer
    Targeted Drug Therapy for Non-Small Cell Lung Cancer. As researchers have learned more about the changes in non-small cell lung cancer (NSCLC) cells that help them grow, they have developed drugs to specifically target these changes. On this page. [ show] When is targeted therapy used?
    04/21/2024 - 10:08 pm | View Website
  • More

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Living News